A Point Of Harmony On Avandia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
What will the REMS redesign process mean for the day-to-day decision-making at FDA? The latest data on use of REMS surely provides a clue: FDA will invoke the new authorities a bit more judiciously than might have been the case a year ago.